drugset / Trial / NCT00936871

The Effect Of Lersivirine (UK-453,061) On Qt Intervals In Healthy Subjects

NCT00936871

Phase 1 Completed 66 enrolled Pfizer
RandomizedCrossoverSingle-blindTreatment

Summary

This study has been designed to investigate the effect of lersivirine on the QT/QTc interval in order to help establish the safety profile of lersivirine.

Timeline

Start
2010-01
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lersivirine Small molecule 2100 mg Oral
Subject Lersivirine Small molecule 2400 mg Oral
Subject Moxifloxacin Small molecule 400 mg

Indications

No indication recorded.